Sigyn Therapeutics, Inc.
SIGY
$3.53
-$0.62-14.94%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.42% | 40.86% | 2.11% | 6.43% | 51.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.35% | 25.78% | 5.02% | 20.85% | 52.08% |
| Operating Income | 33.35% | -25.78% | -5.02% | -20.85% | -52.08% |
| Income Before Tax | 55.55% | -32.15% | -19.26% | 43.47% | -36.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 55.55% | -32.15% | -19.26% | 43.47% | -36.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 55.55% | -32.15% | -19.26% | 43.47% | -36.93% |
| EBIT | 33.35% | -25.78% | -5.02% | -20.85% | -52.08% |
| EBITDA | 33.20% | -25.89% | -5.25% | -21.17% | -53.01% |
| EPS Basic | 65.12% | -15.19% | -4.34% | 55.81% | -3.30% |
| Normalized Basic EPS | 71.18% | -15.18% | 19.01% | 56.33% | -34.30% |
| EPS Diluted | 64.73% | -15.05% | -4.48% | 55.54% | -3.30% |
| Normalized Diluted EPS | 71.18% | -15.18% | 19.01% | 56.33% | -34.30% |
| Average Basic Shares Outstanding | 27.46% | 14.74% | 14.29% | 27.95% | 32.53% |
| Average Diluted Shares Outstanding | 27.46% | 14.74% | 14.29% | 27.95% | 32.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |